Who are DPP-IV Inhibitor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Incretin-based therapy, exenatide and sitagliptin, Saxagliptin + Metformin, Sitagliptin combined with metformin, Sitagliptin (Januvia), Sitagliptin + Metformin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dpp-iv-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

DPP-IV Inhibitor — Competitive Intelligence Brief

DPP-IV Inhibitor (DPP-IV Inhibitor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-IV inhibitor. Area: Diabetes.

phase 2 DPP-IV inhibitor DPP-4 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

DPP-IV Inhibitor (DPP-IV Inhibitor) — Hoffmann-La Roche. DPP-IV inhibitors block the action of dipeptidyl peptidase-4, an enzyme that breaks down incretin hormones, thereby increasing incretin levels and enhancing glucose-dependent insulin secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DPP-IV Inhibitor TARGET	DPP-IV Inhibitor	Hoffmann-La Roche	phase 2	DPP-IV inhibitor	DPP-4
Incretin-based therapy	Incretin-based therapy	Nagaoka Red Cross Hospital	marketed	Incretin mimetic or DPP-4 inhibitor	GLP-1 receptor or DPP-4
exenatide and sitagliptin	exenatide and sitagliptin	AstraZeneca	marketed	GLP-1 receptor agonist and DPP-4 inhibitor combination	GLP-1 receptor (exenatide); DPP-4 (sitagliptin)
Saxagliptin + Metformin	Saxagliptin + Metformin	AstraZeneca	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Sitagliptin (Januvia)	Sitagliptin (Januvia)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Sitagliptin + Metformin	Sitagliptin + Metformin	Baylor College of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-IV inhibitor class)

Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DPP-IV Inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/dpp-iv-inhibitor. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab